Is Annexin Pharmaceuticals AB (publ) (ANNX) Stock About to Get Hot Thursday?

The market has been high on Annexin Pharmaceuticals AB (publ) (ANNX) stock recently. ANNX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Annexin Pharmaceuticals AB (publ) has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ANNX!

See Full ANNX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ANNX Stock Today?

Annexin Pharmaceuticals AB (publ) (ANNX) stock is higher by 1.18% while the S&P 500 is down -0.15% as of 5:09 PM on Thursday, Nov 16. ANNX is higher by $0.01 from the previous closing price of $0.68 on volume of 181,387 shares. Over the past year the S&P 500 has gained 12.64% while ANNX is down -31.68%. ANNX lost -$0.25 per share in the over the last 12 months. To screen for more stocks like Annexin Pharmaceuticals AB (publ) click here.

More About Annexin Pharmaceuticals AB (publ)

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Click Here to get the full Stock Report for Annexin Pharmaceuticals AB (publ) stock.